Law360, New York (February 04, 2008, 12:00 AM ET) -- The race to be the world's anti-influenza drug leader continues to heat up, with Biota's Relenza receiving a leg up in light of a new study that is questioning the effectiveness of Roche Holdings AG's blockbuster Tamiflu.
On Monday, the European Centre for Disease Prevention and Control asserted that Tamiflu may be losing some of its ability to fight off the influenza viruses plaguing Europe this winter after conducting tests on 437 samples of influenza viruses.
“So far, 437 samples of influenza A(H1N1) viruses isolated between...
More Questions Raised Over Tamiflu
To view the full article, take a free trial now.
